Spleen cells of a patient with hairy cell leukemia (Daudi cells)
Alternative Names:
DR alpha chain, HLA class II histocompatibility antigen, HLA class II histocompatibility antigen DR alpha chain, HLA DRA, HLA DRA1, HLA-DRA, HLADRA1, Major histocompatibility complex class II DR alpha, MHC cell surface glycoprotein, MHC class II antigen DRA
MAb IPO-10 defines the antigen, which appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37 and cym. It is expressed on resting B cells and than reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnostics of neoplasms of B cell origins. It reacts with human B cell lines Daudi, Raji, Namalva, EB-3, RPMI-8226 (50% of cells). The MAb does not label T cell lines, blood granulocytes, thymocytes or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This MAb labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70% of B cell CLL and some B-NHL were also positive. IPO-10 reacts with AMML cells and in a majority of Hodgkins disease cases a significant percentage of affected lymph node cells were detected.
200ug/ml of Ab Purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.
SDS-PAGE Analysis of Purified HLA-DRA Mouse Monoclonal Antibody (IPO-10). Confirmation of Integrity and Purity of Antibody.
* VAT and and shipping costs not included. Errors and price changes excepted
